BioLab Holdings, Inc. Launches Its Largest Clinical Trial to Date Evaluating Human Placental Membrane Products
PHOENIX, July 31, 2025 /PRNewswire/ — BioLab Holdings, Inc., a Phoenix-based medical manufacturer specializing in regenerative wound care, has initiated its most comprehensive clinical trial to date. The multicenter, prospective, randomized controlled study will evaluate the efficacy of four human placental membrane (HPM) products in combination with standard of care (SOC) compared to SOC alone in the treatment of nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs).
The trial, formally titled 'A Multicenter, Prospective, Randomized Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers (BIOCAMP),' will enroll 650 subjects across up to 30 clinical sites nationwide.
'This study represents a major milestone in our commitment to advancing wound care through rigorous clinical research,' said Dr. Marshall Medley, chief medical officer at BioLab. 'By evaluating our full suite of amnion-based products in a real-world setting, we aim to provide clinicians with robust data to guide treatment decisions for patients with chronic wounds.'
Participants will be randomized to receive one of four BioLab products—Tri-Membrane Wrap™ (HPM-1), Membrane Wrap™ (HPM-2), Membrane Wrap-Lite™ (HPM-3), or Membrane Wrap-Hydro™ (HPM-4)—in addition to SOC, or SOC alone. Treatments will be applied weekly for up to 12 weeks or until complete wound closure is achieved and confirmed two weeks later. Optional weekly visits will allow for dressing changes in both study arms.
The study is designed to capture real-world clinical outcomes and support the growing body of evidence for the use of placental-derived allografts in chronic wound management.
For more information on BioLab Holdings, Inc. and its regenerative wound care solutions, visit biolabholdings.net.
About BioLab Holdings, Inc.BioLab Holdings, Inc. is a Phoenix-based medical manufacturer focused on wound healing and regenerative medicine. Its product portfolio includes Membrane Wrap Lite™, Tri-Membrane Wrap™, Membrane Wrap™ and Membrane Wrap – Hydro™, all derived from human amniotic membrane. These minimally manipulated allografts are designed to preserve the tissue's natural properties and support healing. BioLab is committed to delivering safe, high-quality products through innovation, education and exceptional customer service. Learn more at biolabholdings.net.
Contact: Kwyn LowePhone: 406.314.5120Email: kwyn@evolveprandmarketing.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysia Sun
13 hours ago
- Malaysia Sun
Smart Jelly for Smart Aging: Chula's High-Protein Pudding Takes Global Stage
BANGKOK , Aug. 5, 2025 /PRNewswire/ -- Chulalongkorn University 's "High-Protein Jelly Pudding with Modified Texture for the Elderly with Swallowing Difficulties," developed by Asst. Prof. Dr. Varanya Techasukthavorn and a team from the Faculty of Allied Health Sciences, won a bronze medal in Geneva , along with a special award from Malaysia . Striking with banana and strawberry flavors, the jelly pudding is easy to consume and provides a high protein content of 7-8 grams per cup to strengthen muscles. It's suitable for the elderly, patients, and those who need additional protein. The team is preparing to scale up to commercial production soon. Smart Jelly for Smart Aging Chula's High-Protein Pudding Takes Global Stage The "High Protein Jelly Pudding with Modified Texture for the Elderly with Swallowing Difficulties" by Asst. Prof. Dr. Varanya Techasukthavorn, Department of Nutrition and Dietetics, Faculty of Allied Health Sciences, Chulalongkorn University , and her team won the Bronze Medal at "The 50th International Exhibition of Inventions Geneva," held on April 9-13, 2025 , in Geneva, Switzerland , and the Prize of Malaysia delegation from Malaysia Delegation from Malaysia . This marks another remarkable innovation that addresses the needs of an aging society and the elderly people who often face problems with reduced food consumption and difficulty chewing and swallowing. Elderly-Friendly Protein Snack under IDDSI Standards Asst. Prof. Dr. Varanya Techasukthavorn, head of the research team, revealed the origin of this innovation: elderly people often have trouble chewing and swallowing food, which causes them to receive insufficient nutrients, resulting in muscle loss. Continuous research on food for people with swallowing difficulties has led to the development of "46 swallowing training foods based on international IDDSI standards." This sparked requests for ready-to-eat snacks that are high in nutrients and safe to swallow for the elderly. Hence, the "High Protein Jelly Pudding with Modified Texture for the Elderly with Swallowing Difficulties" was created as a between-meal supplement with delicious flavors that appeal to Thai tastes for elderly people. The product is marketed under the name "Elderine," developed in collaboration with Banpong Novitat Co., Ltd. "The research and development of the high-protein jelly pudding formula took more than 1 year, going through various processes in the laboratory. Experiments were done to modify the texture and enhance nutritional value, adjusting the proportions of raw ingredients and flavors as well as examining the texture. The product was then evaluated by 30 elderly volunteers before undergoing the production technology that best meets the requirements," Asst. Prof. Dr. Varanya stated. 2-in-1 jelly pudding: high-protein and chewable, an innovation for every age Asst. Prof. Dr. Varanya explained the unique characteristic of the newly developed high-protein jelly pudding: "it differs from the jelly pudding sold in the market in that it has a 2-in-1 texture. The ready-to-eat jelly texture maintains its stability on a spoon and can become a soft pudding texture when lightly mashed with a spoon, helping elderly people chew and consume food even without teeth. Moreover, this high-protein jelly pudding contains up to 7 grams of a special whey protein isolate per cup without hardening the texture or making it bitter. It incorporates modified cassava starch with glucose polymer molecules to achieve a low glycemic index, and the texture is optimized with a balanced blend of carrageenan and other gelling agents. Using advanced production technology, the product can be stored at room temperature for up to 6 months while maintaining the same quality and texture. Currently, two flavors have been developed to suit the Thai palate: banana and strawberry. Each cup of jelly pudding provides 70-80 calories of energy and 7-8 grams of easily digestible protein, equivalent to one chicken egg. It serves as a healthy snack that can be consumed up to 2 cups per day. Besides the elderly, the product is suitable for various groups of consumers, e.g., those who have recently had their teeth or wisdom teeth removed, causing difficulty chewing; teenagers who want to increase their protein intake; cancer patients who need a lot of protein supplements; and those who would like to build muscle, etc. This high-protein jelly pudding innovation received support from Dr. Chaiwut Gamonpilas from the National Metal and Materials Technology Center (MTEC), National Science and Technology Development Agency (NSTDA), who conducted an oral tribology test on the texture and slipperiness of the jelly pudding. Toward Medical Food Innovation for the Elderly Currently, this product is in the process of patent application. For the future, Asst. Prof. Dr. Varanya shared plans to register the product as a special-purpose food in the form of medical food. In collaboration with a research team (Asst. Prof. Dr. Pattra Wattanapan from the Faculty of Medicine, Khon Kaen University), a human research study will be conducted to test the effectiveness of the high-protein jelly pudding product on increasing muscle mass in elderly people. The team is also expanding collaboration with a research team from Japan for commercial production of the jelly pudding. It is expected to be available in the market around this coming October. Asst. Prof. Dr. Varanya is committed to studying food products for those with swallowing difficulties, with plans to develop products in other forms, such as Thai desserts for the elderly, as well as functional food products with other added nutrients essential for the elderly, like fiber to help with digestion. For the full release and more images, please visit: About Chulalongkorn University Chulalongkorn University has made the world's top 50 university list for employment outcomes, which reflects both the high employment rate and work ability of Chula graduates. The university is also listed as the best in Thailand for the 15th Consecutive Year (since 2009), according to the newly released QS World University Rankings 2024, putting Chula at 211th in the world, up from 244th last year. Social Media: Facebook: Youtube: Linkedin:
Malaysian Reserve
a day ago
- Malaysian Reserve
Nuna Selected by White House and CMS to Join Landmark Health Tech Ecosystem Initiative
SAN FRANCISCO, Aug. 4, 2025 /PRNewswire/ — Nuna announced its selection to join the Centers for Medicare & Medicaid Services (CMS) Health Tech Ecosystem, a landmark public-private initiative designed to transform healthcare for Americans. The initiative was unveiled at a White House event on Wednesday by President Donald Trump, CMS Administrator Dr. Mehmet Oz, HHS Secretary Robert F. Kennedy Jr., and Amy Gleason, Acting Administrator of DOGE. The event was attended by a select group of healthcare leaders and innovators, including Nuna Founder and CEO, Jini Kim. As part of the ecosystem, Nuna will contribute its expertise to two cornerstone efforts: Conversational AI Assistance and Diabetes & Obesity Prevention and Management. 'We're honored to stand alongside CMS in this bold and necessary step forward in healthcare,' said Jini Kim. 'We believe health isn't just built in the hospital or clinic; it's forged in the small moments of our daily lives. That's why we created Nuna, a trusted digital companion to help people succeed on their health journey, one day at a time.' Nuna's pledge is centered on its AI-powered digital engagement platform. Nuna's app empowers patients to confidently manage their chronic conditions through a combination of 24/7 conversational support, motivating gamification, and direct linkage to their clinical care team. This integrated approach drives powerful results: 72% of users with uncontrolled hypertension achieve control and 73% remain active after six months. By connecting daily patient behavior to the clinical team, Nuna bridges a critical gap in today's healthcare landscape by enabling timely, proactive intervention by care teams for their patients. 'Nuna has been a game changer for patients struggling with chronic conditions,' said David Ansell, MD, of Rush University System for Health and a Nuna development partner. 'It extends care from the clinic to the home and its AI enhanced education engages patients in behavioral change that persists over time. The result being better blood pressure control and improved health behaviors. Early results suggest it can crack the code on chronic disease self-management by engaging people to attend to their health when they are in their homes. This type of tech innovation has great potential to transform primary and preventive care across the US.' About Nuna Nuna is a digital health company dedicated to transforming chronic care by empowering patients and their clinicians. Its AI-driven platform provides personalized, continuous support to help people manage their health and chronic conditions in the moments that matter most. Nuna partners with health systems and health plans to improve patient outcomes, enhance care team efficiency, and reduce the overall cost of care. For more information about Nuna's participation in the CMS Digital Health Ecosystem, visit or contact press@
The Star
a day ago
- The Star
Women face more injury risks in car crashes, yet dummies are modelled after men
Maria Weston Kuhn had one lingering question about the car crash that forced her to have emergency surgery during a vacation in Ireland: Why did she and her mother sustain serious injuries while her father and brother, who sat in the front, emerge unscathed? 'It was a head-on crash and they were closest to the point of contact,' said Kuhn, now 25, who missed a semester of college to recover from the 2019 collision that caused her seat belt to slide off her hips and rupture her intestines by pinning them against her spine. 'That was an early clue that something else was going on.' When Kuhn returned home to Maine, she found an article her grandma had clipped from Consumer Reports and left on her bed. Women are 73% more likely to be injured in a frontal crash, she learned, yet the dummy used in vehicle tests by the National Highway Traffic Safety Administration dates back to the 1970s and is still modelled almost entirely off the body of a man. Kuhn, who is starting law school at New York University this fall, took action and founded the nonprofit Drive US Forward. Its aim was to raise public awareness and eventually encourage members of Congress to sign onto a bill that would require NHTSA to incorporate a more advanced female dummy into its testing. The agency has the final word on whether cars get pulled from the market, and the kind of dummy used in its safety tests could impact which ones receive coveted five-star ratings. 'It seems like we have an easy solution here where we can have crash test dummies that reflect an average woman as well as a man,' Sen. Deb Fischer, a Nebraska Republican who has introduced the legislation the past two sessions said. Senators from both parties have signed onto Fischer's 'She Drives Act,' and the transportation secretaries from the past two presidential administrations have expressed support for updating the rules. But for various reasons, the push for new safety requirements has been moving at a sluggish pace. That's particularly true in the United States, where much of the research is happening and where around 40,000 people are killed each year in car crashes. The crash test dummy currently used in NHTSA five-star testing is called the Hybrid III, which was developed in 1978 and modelled after a 5-foot-9, 171-pound (175cm, 77.5kg) man – the average size in the 1970s but about 29 pounds (13kg) lighter than today's average. What's known as the female dummy is essentially a much smaller version of the male model with a rubber jacket to represent breasts. It's routinely tested in the passenger seat or the back seat but seldom in the driver's seat, even though the majority of licensed drivers are women. 'What they didn't do is design a crash test dummy that has all the sensors in the areas where a woman would be injured differently than a man,' said Christopher O'Connor, president and CEO of the Farmington Hills, Michigan-based Humanetics Group, which has spent more than a decade developing and refining one. A female dummy from Humanetics equipped with all of the available sensors costs around US$1mil (RM425mil), about twice the cost of the Hybrid used now. But, O'Connor says, the more expensive dummy far more accurately reflects the anatomical differences between the sexes – including in the shape of the neck, collarbone, pelvis, and legs, which one NHTSA study found account for about 80% more injuries by women in a car crash compared to men. A female crash test dummy is shown on an impact rig. Photo: PAUL SANCYA/AP For safety tests Such physical dummies will always be needed for vehicle safety tests, and to verify the accuracy of virtual tests, O'Connor said. Europe incorporated the more advanced male dummy developed by Humanetics' engineers, the THOR 50M (based on a 50th percentile man), into its testing procedures soon after Kuhn's 2019 crash in Ireland. Several other countries, including China and Japan, have adopted it as well. But that model and the female version the company uses for comparison, the THOR 5F (based on a 5th percentile woman), have been met with skepticism from some American automakers who argue the more sophisticated devices may exaggerate injury risks and undercut the value of some safety features such as seat belts and airbags. Bridget Walchesky, 19, had to be flown to a hospital, where she required eight surgeries over a month, after a 2022 crash near her home in Sheboygan, Wisconsin, that killed her friend, who was driving. While acknowledging the seat belt likely saved her life, Walchesky said some of the injuries – including her broken collarbone – were the result of it pinning her too tightly, which she views as something better safety testing focused on women could improve. 'Seat belts aren't really built for bodies on females,' Walchesky said. 'Some of my injuries, the way the force hit me, they were probably worsened.' The Alliance for Automotive Innovation, an industry trade group, said in a statement to the AP that the better way to ensure safety – which it called its top priority – is through upgrades to the existing Hybrid dummy rather than mandating a new one. 'This can happen on a faster timeline and lead to quicker safety improvements than requiring NHTSA to adopt unproven crash test dummy technology,' the alliance said. Humanetics' THOR dummies received high marks in the vehicle safety agency's early tests. Using cadavers from actual crashes to compare the results, NHTSA found they outperformed the existing Hybrid in predicting almost all injuries – including to the head, neck, shoulders, abdomen and legs. A THOR-5F female crash test dummy is shown on an impact rig. Photo: PAUL SANCYA/AP Critical views A separate review by the Insurance Institute for Highway Safety, a research arm funded by auto insurers, was far more critical of the dummy's ability to predict chest injuries in a frontal crash. Despite the vast expansion in the number of sensors, the insurance institute's testing found, the male THOR dummy was less accurate than the current Hybrid dummies, which also had limitations. 'More isn't necessarily better,' said Jessica Jermakian, senior vice president for vehicle research at IIHS. 'You also have to be confident that the data is telling you the right things about how a real person would fare in that crash.' NHTSA's budget plan commits to developing the female THOR 5F version with the ultimate goal of incorporating it into the testing. But there could be a long wait considering the THOR's male version adopted by other countries is still awaiting final approval in the US. A 2023 report by the Government Accountability Office, which conducts research for Congress, cited numerous 'missed milestones' in NHTSA's development of various crash dummy enhancements – including in the THOR models. Kuhn acknowledges being frustrated by the slow process of trying to change the regulations. She says she understands why there's reluctance from auto companies if they fear being forced to make widespread design changes with more consideration for women's safety. 'Fortunately, they have very skilled engineers and they'll figure it out,' she said. – AP
